报价延迟最少15分钟:2026/03/09 19:53 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.29 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.43/1.68
|
|
企业价值
843.24M
|
| 资产负债 |
|
每股账面净值
10.78
|
| 现金流量 |
|
现金流量率
0.10
|
| 损益表 |
|
收益
370.50M
|
|
每股收益
7.87
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF,and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions. |
